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Abstracts / Pediatric Hematology Oncology Journal 1 (2016) S1eS33 S23disease and death. 2 children where TCR a/b depletion and CD3/19 se-
lection was used died of progressive leukoencephalopathy probably of
viral etiology.
Conclusions: Haploidentical stem cell transplantation is a feasible option
for cure in children with lifethreatening benign disorders where no
compatible family or matched unrelated donor has been found with
engraftment rates of 75% and overall survival of 55%. Up to 30% can develop
CMV viral reactivation and acute GVHD. PTCY in infants caused lethal
neurological side effects andmortality and should not be recommended. In
our series, we have had superior outcome with the use of PTCy compared
to ex vivoT depletionwith survival rates of 55%. The cost of themonoclonal
antibodies alone is about 12 lakhs making this procedure twice as
expensive compared to PTCY. Careful patient selection will improve out-
comes using this simple but cost effectivemethod of treating childrenwith
benign haematological conditions in the future.
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Introduction: Thalassemias are the most common inherited single gene
disorders of the hemoglobin production prevalent all across the world
especially in the Thalassemia belt extending eastward from the Mediter-
ranean to South East Asia. Although conservative management with reg-
ular blood transfusions and effective chelation have improved the short
term outlook, allogeneic bone marrow transplantation provides the only
option of complete cure.
Methods: We retrospectively analyzed the outcomes of patients diag-
nosed with Thalassemia who underwent allogeneic hematopoietic
stem cell transplantation at our institute from November 2004 to July
2016.
Results: One hundred Thalassemia patients [Males n¼56 (56 %); Females
n¼44 (44%)] with a median age of 7 years (range 2 to 24 years) under-
went HSCT during this period. Seventy six (76%) were classiﬁed as Pesaro
Class 2 and 18 (18%) as Class 3. Six (6%) patients were classiﬁed as Pesaro
Class 1. The donor type was Matched sibling in 84 (84%), Matched Related
in 2 (2%), Matched Unrelated in 9 (9 %) and Haploidentical in 5 (5 %)
patients. Stem cell source was Marrow, Peripheral stem cells and Cord in
67 (67%), 29 (29%) and 1 (1%) patients respectively. Two patients (2%)
received both marrow as well as peripheral stem cells, whereas 2 (1%
each) received cord blood and cord plus marrow respectively. Of the 29
PBSCTs done, 4 were from a matched unrelated donor (MUD) and 5 (5%)
were from haploidentical donors. The conditioning regimens used con-
sisted of Flu-Bu-Cy-ATG (n¼45) [45%], BU-CY-ATG (n¼25) [25%], FLU-
THIO-TREO-ATG (n¼16)[16%], FLU-THIO-TREO (n¼8) [8%], FLU-BU-CY-
THIO-ATG (n¼2) [2%], BU-CY (n¼2) [2%] and FLU-BU-CY-RITUXIMAB,
FLU-BU-CY-TBI AND each [0.9% each). Majority of the recipients received
Cyclosporine and Methotrexate as GVHD prophylaxis (n¼88; 88%). The
median MNC and CD34 cell dose for patients who had received marrow
and/or peripheral stem cells was 7.4108/kg (range 2.1 to 23 108/kg)
and 4.5106/kg (range 0.66 to 38 106/kg) respectively. The patient who
underwent cord blood transplant received a MNC dose of 0.51X 108/kg
and a CD34 dose of 0.4X106/kg. Hematological recovery was seen in all
patients except two (2) patients that also included the cord blood
transplant recipient, who died before engraftment. Neutrophil and
platelet engraftment occurred at a median of 14 days (range, 8-24 days)
and 21 days (range, 8-72 days), respectively. Thirty seven (37%) patients
developed veno-occlusive disease. Thirty three patients (33%) developed
Grade I-IV GVHD, 22 (23.3%) had Grade II-IV GVHD and 4 (4%) had Grade
III-IV GVHD. Six (6%) patients had chronic GVHD. At day +28, sixty (60%)
patients showed more than 90% donor chimersim and 34 (34%) had
mixed chimerism. Five (5%) patients had expired before day +28 before
chimerism could be done. One patient had primary rejection. Six patients
(6%) patients experienced secondary graft rejection. Amongst patients
who were more than day 100 at the time of analysis, the Treatment-related mortality (TRM) for the whole cohort was 12%. TRM was 8.3% and
33.34% for Class 2 and class 3 patients respectively. At a median follow up
of 25 months, overall survival and thalassemia free survival were 85.3%
and 77.3% respectively.
Conclusion: Similar outcomes have been reported from developed
countries. Outcome of Class 3 patients still continues to be poor and VOD
rates are high in this patient group.
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Background: Allogenic Hematopoietic Stem Cell Transplantation (HSCT)
has been an established curative option for a number of non-malignant
and malignant disorders. Unfortunately, most children in our country are
unable to avail of this option due to non-affordability and its non-avail-
ability in public sector hospitals. We share our experience of establishing a
Hematopoietic Stem Cell Transplant Unit at Lokmanya Tilak Municipal
General Hospital, a civic hospital in Mumbai. Till date, over one year, we
have performed eight hematopoietic stem cell transplants for various
indications.
Objective: To share the experience and challenges in establishing a HSCT
unit in a Public Hospital.
Method: The need for a Hematopoietic Stem Cell Transplant (HSCT) centre
was always felt with indications for HSCT being identiﬁed in increasing
number of children. The idea of setting up a HSCTcentre, though conceived
in 1998, could not materialize till 2012, as there was no source for funding
available. After the major hurdle of funds was taken care of by a philan-
thropic organization, the task of administrative approval, space allocation
and getting the desired infrastructure in place began in 2013. Funds were
utilized for building the state-of-the-art 20-bedded Pediatric Hematology-
Oncology Unit with one bedded HSCT centre. The purchase of equipment
and staff recruitment was done simultaneously. Training of the selected
staff, including the paramedical personnel and team building was initiated.
The process of team building was taken up before the unit became func-
tional and experts with experience in HSCT were invited to join the
existing team of doctors in the Pediatric Hematology-Oncology Division.
Donor funding was ensured for pre-HSCT workup, process of trans-
plantation and post-transplant care. Patients in whom HSCT was consid-
ered curative and who had a matched sibling donor were considered for
transplant.
Results: The HSCT unit was operational by August 2015 and 8 patients
have been transplanted till date. These include 4 children with Severe
Aplastic Anemia (SAA), 3 with Thalassemia Major (TM) and 1 infant with
Severe Combined Immune Deﬁciency- Reticular Dysgenesis (SCID). HSCT
with matched sibling donor was done in 7 patients, whereas, father was
the donor for the infant with SCID with a 9/10 match. Reduced Intensity
Conditioning (RIC) consisting of Flu-Cy-ATG was used in patients with SAA
and Treo-Thio-Flu-ATG was administered to the baby with SCID. For 2 of 3
TM belonging to class II by Pesaro classiﬁcation, myeloablative regimen
consisting of Bu-Cy-ATG was used, whereas the third thalassemic, who
was Class III, a reduced intensity regimen with Treo-Thio-Flu-ATG was
given. Peripheral blood stem cells (PBSC) was the source of stem cells in
SAA and SCID, whereas bone marrow harvest was done for TM. Challenges
faced included blood group mismatch in 6 of these patients - major ABO
mismatch in 3, minor ABOmismatch in 2 of them and 1 with Rhmismatch.
Seven of the 8 patients are free of their disease, with no GVHD or any other
complications at a follow up ranging from 20 days to 1 year 8 days. The
infant with SCID died of adenoviral infection during immediate post-
transplant period during the severely neutropenic phase.
Conclusion: It is feasible to set up a HSCT unit in a public sector hospital if
one has the vision, passion and commitment. Presently, there are hardly
